{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:13:17Z","timestamp":1780582397574,"version":"3.54.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Depending on the cellular context and cancer type, FOXP1 functions as an oncogene or a tumor suppressor. However, the clinical role of FOXP1 in hematologic malignancies has not been studied comprehensively. This study systematically analyzed the association of FOXP1 expression with clinical outcomes, including prognosis and immunotherapeutic response, as well as biological functions across a range of hematological cancers. Our findings demonstrated that FOXP1 expression was dysregulated in several hematological malignancies and was associated with poor prognosis. FOXP1 was highly expressed in acute myeloid leukemia (AML). Methylation of the FOXP1 promoter was significantly reduced in patients with AML compared to the healthy control subjects and those with myelodysplastic syndromes. FOXP1 promoter methylation showed an inverse relationship with FOXP1 gene expression in AML. Moreover, FOXP1 expression was associated with the tumor infiltration of B cells, natural killer cells, and T cells, as well as the cytolytic score across various hematologic malignancies. Our data showed that FOXP1 expression was a promising biomarker for predicting responses to immunotherapy in AML patients. Functionally, the knockdown of FOXP1 demonstrated antileukemic effects, including reduced AML cell proliferation and cell cycle arrest in the G1-S phase. In conclusion, this study systematically investigated the role of FOXP1 across a spectrum of hematological malignancies and demonstrated that FOXP1 was a promising prognostic biomarker and a potential therapeutic target in AML and other hematological malignancies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1569641","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:51:27Z","timestamp":1751435487000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["FOXP1 is associated with oncogenesis and clinical outcomes in hematologic malignancies"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiang-mei","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-xi","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-wan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-yu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-wei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1365851","article-title":"Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC","volume":"59","author":"Paul","year":"2018","journal-title":"Leukemia Lymphoma"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000475530","article-title":"Tumor heterogeneity in lymphomas: A different breed","volume":"85","author":"Schurch","year":"2018","journal-title":"Pathobiology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2016.08.005","article-title":"Molecular biomarkers in acute myeloid leukemia","volume":"31","author":"Prada-Arismendy","year":"2017","journal-title":"Blood Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0116","article-title":"Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"O\u2019Donnell","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jama.2018.20416","article-title":"New acute myeloid leukemia therapy","volume":"321","author":"Voelker","year":"2019","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01144-7","article-title":"From DNA sequencing to clinical trials: finding new targeted drugs for acute myeloid leukemia","volume":"79","author":"Yilmaz","year":"2019","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","article-title":"Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review","volume":"14","author":"Camicia","year":"2015","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad057","article-title":"p38-mediated FOXN3 phosphorylation modulates lung inflammation and injury through the NF-kappaB signaling pathway","volume":"51","author":"Zhu","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13046-018-0894-0","article-title":"FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC","volume":"37","author":"Cao","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2523","article-title":"The evolution of Fox genes and their role in development and disease","volume":"10","author":"Hannenhalli","year":"2009","journal-title":"Nat Rev Genet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7150\/thno.31716","article-title":"Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR","volume":"9","author":"Du","year":"2019","journal-title":"Theranostics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2223","article-title":"The emerging roles of forkhead box (Fox) proteins in cancer","volume":"7","author":"Myatt","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-626176","article-title":"The forkhead transcription factor FOXP1 represses human plasma cell differentiation","volume":"126","author":"van Keimpema","year":"2015","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e3000270","DOI":"10.1371\/journal.pbio.3000270","article-title":"Foxp1 is critical for the maintenance of regulatory T-cell homeostasis and suppressive function","volume":"17","author":"Ren","year":"2019","journal-title":"PloS Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41598-017-19109-9","article-title":"A de novo FOXP1 truncating mutation in a patient originally diagnosed as C syndrome","volume":"8","author":"Urreizti","year":"2018","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2014.2197","article-title":"FOXP1 has a low expression in human gliomas and its overexpression inhibits proliferation, invasion and migration of human glioma U251 cells","volume":"10","author":"Xue","year":"2014","journal-title":"Mol Med Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3390\/ijms17091501","article-title":"Downregulation of FOXP1 inhibits cell proliferation in hepatocellular carcinoma by inducing G1\/S phase cell cycle arrest","volume":"17","author":"Wang","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e18294","DOI":"10.1111\/jcmm.18294","article-title":"An integrated analysis of the anticarcinogenic role of forkhead box protein 1 in oesophageal squamous cell carcinoma","volume":"28","author":"Ye","year":"2024","journal-title":"J Cell Mol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403813","article-title":"FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations","volume":"19","author":"Wlodarska","year":"2005","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1228932","article-title":"The significance of FOXP1 in diffuse large B-cell lymphoma","volume":"58","author":"Gascoyne","year":"2017","journal-title":"Leukemia Lymphoma"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10735-005-6521-3","article-title":"The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin\u2019s lymphoma","volume":"36","author":"Brown","year":"2005","journal-title":"J Mol Histol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.14670\/HH-26.213","article-title":"FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type","volume":"26","author":"Espinet","year":"2011","journal-title":"Histol Histopathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1159\/000212058","article-title":"FOXP1 expression predicts polymorphic histology and poor prognosis in gastric mucosa-associated lymphoid tissue lymphomas","volume":"26","author":"Han","year":"2009","journal-title":"Dig Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.299","article-title":"FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas","volume":"30","author":"Brown","year":"2016","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7150\/jca.85906","article-title":"FOXP1-GINS1 axis promotes DLBCL proliferation and directs doxorubicin resistance","volume":"14","author":"Chen","year":"2023","journal-title":"J Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.omto.2022.05.011","article-title":"Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia","volume":"26","author":"Xu","year":"2022","journal-title":"Mol Ther Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/cam4.4905","article-title":"Pan-cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1477100","article-title":"Bioinformatic characterization of STING expression in hematological Malignancies reveals association with prognosis and anti-tumor immunity","volume":"16","author":"Wen","year":"2025","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"19107","DOI":"10.1038\/s41598-023-46552-8","article-title":"Comprehensive characterization of TGFB1 across hematological Malignancies","volume":"13","author":"Wang","year":"2023","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-019-1851-1","article-title":"Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia","volume":"17","author":"Xu","year":"2019","journal-title":"J Trans Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.08.019","article-title":"Immunogenomic landscape of hematological Malignancies","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13229-017-0172-6","article-title":"Prospective investigation of FOXP1 syndrome","volume":"8","author":"Siper","year":"2017","journal-title":"Mol Autism"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2017-104579","article-title":"FOXP1-related intellectual disability syndrome: a recognisable entity","volume":"54","author":"Meerschaut","year":"2017","journal-title":"J Med Genet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2023.194992","article-title":"The functions of FOXP transcription factors and their regulation by post-translational modifications","volume":"1866","author":"Gao","year":"2023","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0461","article-title":"Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas","volume":"10","author":"Fox","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205835","article-title":"Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers","volume":"21","author":"Zabarovsky","year":"2002","journal-title":"Oncogene"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20583","article-title":"Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia","volume":"67","author":"Banham","year":"2007","journal-title":"Prostate"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-396","article-title":"FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities","volume":"14","author":"L\u2019Abbate","year":"2014","journal-title":"BMC Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008585","article-title":"FOXP1 regulates oxidative stress, SIRT1 expression, and resistance to chemotherapies in acute myeloid leukemia cells","volume":"7","author":"Levavasseur","year":"2023","journal-title":"Blood Adv"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-747436","article-title":"PUMILIO\/FOXP1 signaling drives expansion of hematopoietic stem\/progenitor and leukemia cells","volume":"129","author":"Naudin","year":"2017","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106296","article-title":"MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation","volume":"89","author":"Seipel","year":"2020","journal-title":"Leukemia Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/15384101.2019.1704537","article-title":"miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1\/ATG14 pathway","volume":"19","author":"Hu","year":"2020","journal-title":"Cell Cycle"},{"key":"B48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-380866-0.60002-2","article-title":"DNA methylation and cancer","volume":"70","author":"Kulis","year":"2010","journal-title":"Adv Genet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/ijms19041166","article-title":"Defining driver DNA methylation changes in human cancer","volume":"19","author":"Pfeifer","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1101\/gr.269233.120","article-title":"DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia","volume":"31","author":"Giacopelli","year":"2021","journal-title":"Genome Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.937069","article-title":"FOXP family DNA methylation correlates with immune infiltration and prognostic value in NSCLC","volume":"13","author":"Hu","year":"2022","journal-title":"Front Genet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/s41419-020-03007-6","article-title":"A novel epigenetic regulation of circFoxp1 on Foxp1 in colon cancer cells","volume":"11","author":"Luo","year":"2020","journal-title":"Cell Death Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3109\/08830185.2013.816698","article-title":"Forkhead Box P family members at the crossroad between tolerance and immunity: a balancing act","volume":"33","author":"Fleskens","year":"2014","journal-title":"Int Rev Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155169","article-title":"Participation of B cell in immunotherapy of cancer","volume":"255","author":"Chandnani","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3828","article-title":"Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer","volume":"10","author":"Hu","year":"2021","journal-title":"Cancer Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12885-015-1282-1","article-title":"Tenovin-6-mediated inhibition of SIRT1\/2 induces apoptosis in acute lymphoblastic leukemia (ALL) cells and eliminates ALL stem\/progenitor cells","volume":"15","author":"Jin","year":"2015","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1569641\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:51:28Z","timestamp":1751435488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1569641\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2025.1569641"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1569641","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"article-number":"1569641"}}